Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study

• Main Authors: Irene Moreno (Author), Tatiana Hernández (Author), Emiliano Calvo (Author), Salvador Fudio (Author), Carmen Kahatt (Author), Cristian Fernández (Author), Jorge Luis Iglesias (Author), Gema Corral (Author), Laura Pérez-Ramos (Author), Lola Montilla (Author), Ali Zeaiter (Author), Rubin Lubomirov (Author)
• Format: Book
• Published: MDPI AG, 2024-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

This open-label, two-way, crossover, phase Ib drug-drug interaction study investigated whether the pharmacokinetics (PKs) and safety profile of lurbinectedin (LRB) are affected by co-administration of a moderate CYP3A4 inducer (bosentan, BOS) in adult patients with advanced solid tumors. Eleven pati...